ストックスクリーナーアプリを入手
1.88
6.00%
-0.12
前日終値:
$2.00
開ける：
$2
24時間の取引高:
33,718
Relative Volume:
0.42
時価総額：
$11.51M
収益：
-
当期純損益:
$-10.14M
株価収益率:
-1.0115
EPS:
-1.8587
ネットキャッシュフロー:
$-23.55M
1週間 パフォーマンス:
+1.08%
1か月 パフォーマンス:
+14.63%
6か月 パフォーマンス:
-29.06%
1年 パフォーマンス:
+39.26%
1日の値動き範囲:
$1.87
$2.07
1週間の範囲:
$1.80
$2.2359
52週間の値動き範囲:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
名前
Chemomab Therapeutics Ltd Adr
セクター
電話
972-77-331-0156
住所
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.87 | 12.31M | 0 | -10.14M | -23.55M | -1.8587 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.10 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
735.93 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
682.03 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
310.31 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
280.61 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-13 | 開始されました | Maxim Group | Buy |
| 2024-05-06 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-12-19 | 再開されました | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr (CMMB) 最新ニュース
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday - Defense World
Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews
Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 4.5% – Time to Sell? - Defense World
Chemomab’s nebokitug shows disease-modifying potential in PSC trial - Investing.com
Chemomab’s nebokitug shows disease-modifying potential in PSC trial By Investing.com - Investing.com UK
Chemomab Therapeutics (NASDAQ:CMMB) Cut to “Hold” at Zacks Research - Defense World
Chemomab reports positive 48-week data for PSC drug nebokitug - Investing.com
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com
Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - sharewise.com
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study - Yahoo Finance
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - sharewise.com
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs - Nasdaq
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - sharewise.com
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - sharewise.com
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - sharewise.com
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - sharewise.com
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases - Nasdaq
Chemomab Therapeutics Ltd Share Price ADR Each Representing 80 Ord Shares SPON - Hargreaves Lansdown
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com
KURA Stock Rises More Than 15% This Past Week: Here's Why - Yahoo Finance
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise.com
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Nasdaq
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - The Globe and Mail
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Finviz
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Chemomab Therapeutics to Present at October 2024 Investor Conferences By Investing.com - Investing.com
Chemomab secures $10 million in PIPE financing - Investing.com
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Chemomab Therapeutics (CMMB) Stock Trends and Sentiment 2025 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Forecast and Price Target 2026 - MarketBeat
Chemomab Therapeutics Ltd. Sponsored ADR Earnings and Revenue – NASDAQ:CMMB - TradingView — Track All Markets
symbol__ Stock Quote Price and Forecast - CNN
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC - Yahoo Finance
Chemomab Therapeutics LtdADR (CMMB) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Chemomab Therapeutics (CMMB) - Zacks Investment Research
Chemomab Therapeutics (CMMB) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
What date does Chemomab Therapeutics's (CMMB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance
CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Technical Analysis - Chartmill
Chemomab Therapeutics (CMMB) Institutional Ownership 2026 - MarketBeat
Chemomab Therapeutics Ltd Adr (CMMB) 財務データ
収益
当期純利益
現金流量
EPS
1.60%
1.61%
大文字化:
|
ボリューム (24 時間):